Investors

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that at its Annual General Meeting held earlier today resolutions 1-4 were duly passed.  Resolution 5, a Special Resolution which sought to give the Directors power to issue new ordinary shares for cash other than to the Company’s shareholders on a pro rata basis, was not passed.

The result of the vote on Resolution 5 does not affect the strategy or the day-to-day running of the business and the Directors do not currently envisage that the business would need to raise new funds through the issue of new shares on a non pre-emptive basis before the 2026 AGM. Should such need arise, a separate General Meeting would be convened to seek shareholder approval at the relevant time.

The full voting results will be available on the website in due course here: https://www.optibiotix-ir.com/content/investors/

 

For further information, please contact:   OptiBiotix Health plc		www.optibiotix.com
Neil Davidson, Chairman	Contact via Walbrook below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD and Broker)		Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Walbrook PR Ltd		Mob: 07876 741 001
Anna Dunphy

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.